Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis

2017 ◽  
Vol 24 (9) ◽  
pp. 750-758 ◽  
Author(s):  
M. Buti ◽  
R. Domínguez-Hernández ◽  
I. Oyagüez ◽  
M. A. Casado ◽  
R. Esteban
Keyword(s):  
Chronic Hepatitis ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Cost Effectiveness Analysis ◽  
Advanced Fibrosis ◽  
Hepatitis C Treatment ◽  
Effectiveness Analysis

scholarly journals Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment

2014 ◽  
Vol 50 (2) ◽  
pp. 345-352 ◽  
Author(s):  
Carine Raquel Blatt ◽  
Bernd Storb ◽  
Nikolai Mühlberger ◽  
Mareni Rocha Farias ◽  
Uwe Siebert
Keyword(s):  
Chronic Hepatitis ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Cost Effectiveness Analysis ◽  
Sensitivity Analyses ◽  
Hepatitis C Treatment ◽  
Effectiveness Analysis ◽  
First Choice ◽  
Genotype 2

Brazilian Guidelines to HCV treatment (2007) recommended that the first choice treatment for patients with chronic hepatitis C (CHC) and genotype 2 or 3 is interferon alpha (IFN) plus ribavirin (RBV) for 24 weeks. The aim of this study is compare the cost and effectiveness to Hepatitis C treatment in patients with genotype 2 or 3 of peginterferon alpha (PEG) as the first choice of treatment within PEG for those that do not respond to IFN. The target population is CHC patients with genotype 2 or 3 in Brazil. The interventions are: PEG-SEC (first IFN plus RBV for 24 weeks, after, for non-responders and relapsers subsequently PEG plus RBV for 48 weeks); PEG-FIRST24 (PEG+RBV for 24 weeks). The type of the study is cost-effectiveness analysis. The data sources are: Effectiveness data from meta-analysis conducted on the Brazilian population. Treatment cost from Brazilian micro costing study is converted into USD (2010). The perspective is the Public Health System. The outcome measurements are Sustained Viral Response (SVR) and costs. PEG-FIRST24 (SVR: 87.8%, costs: USD 8,338.27) was more effective and more costly than PEG-SEC (SVR: 79.2%, costs: USD 5,852.99). The sensitivity analyses are: When SVR rates with IFN was less than 30% PEG-FIRST is dominant. On the other hand, when SVR with IFN was more then 75% PEG-SEC is dominant (SVR=88.2% and costs USD $ 3,753.00). PEG-SEC is also dominant when SVR to PEG24 weeks was less than 54%. In the Brazilian context, PEG-FIRST is more effective and more expensive than PEG-SEC. PEG-SEC could be dominant when rates of IFN therapy are higher than 75% or rates of PEG24 therapy are lower than 54%.

Sign in / Sign up

Export Citation Format

Share Document